home > news


Leading life science technology companies create integrated software solution to simplify clinical research activities and improve operational processes


phone (267) 550 0936
email 1189 Lancaster Ave, Berwyn, PA 19312

AARDEX and Cambridge Cognition Join Forces to Bring Next-Level Adherence Oversight to Hybrid and Decentralized Clinical Trials

Seamless integration of adherence and research data protects participant safety and data quality, with no additional burden for clinical trial sites or participants


phone +32 4 374 86 30
email TheLabs - Liege Science Park, 15/1, rue bois St Jean, 4102 Seraing Belgium

Gerresheimer presents its new Clinical Trial Kit to accelerate drug development

Düsseldorf/Paris, February 1, 2023. Gerresheimer presents its new Clinical Trial Kit at Pharmapack in Paris. This kit consists of sterile Gx RTF vials in nest and tub or tray with matching closures and is tailored to requirements to support the development of new drugs, vaccines and biologics in early phases. The Clinical Trial Kit is suitable for small batch manufacturing from first line trials to validation and clinical batches. It can be ordered in six different configurations of Gx RTF Glass Vials. Kits including Gx Elite and Gx RTF COP vials will follow soon. More>>

phone +49-(0)211/61 81-00
email Klaus-Bungert-Str. 4, 40468 Duesseldorf, Germany

Live from Pharmapack: Pharmapack Drug Delivery Index hits record high

Rapid recovery in the Index – just seven months after significant lows in 2022 – points to a strong global recovery in industry outlook and confidence.


phone +31(0)20 708 1637
email Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France

Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics

Oxford, UK, 1st February 2023: Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials. The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics on receptor sets both novel and complimentary to its lead compound. More>>

phone +44 (0) 1865 749234
web orbit
email Schrödinger Building, Heatley Rd, Oxford OX4 4GE


Etihad Cargo has achieved 80.5 per cent OTP for freighter departures and 84.1 per cent OTP for freighter arrivals, ahead of its 80 per cent target. The carrier surpassed its 85 per cent DAP target, achieving 86.6 per cent • PharmaLife performance conti


phone +971 2 505 4721
email Cargo Terminal, Abu Dhabi International Airport

Clinerion is part of Citeline, a Norstella company!

January 30, 2023 – We are pleased to officially announce that Clinerion has become part of Citeline, a Norstella company. Norstella is now poised to be one of the world’s largest pharma intelligence solutions providers on the market. More>>

phone +41 61 865 60 60
email Elisabethenanlage 11, 4051 Basel, Switzerland

DoKaSch to provide cooling containers for El Al for pharma transport

El Al Israel Airlines has signed a master rental agreement with DoKaSch Temperature Solutions for the usage of ‘Opticooler’ containers. The airline will benefit from the active cooling container for its pharmaceutical shipments to and from Israel, DoKaSch said, being able to safely transport temperature-sensitive products to and from its headquarters at Ben Gurion Airport in the belly of its passenger fleet as well as a dedicated cargo aircraft. More>>

phone +49 2602 940202
email Feincheswiese 3, 56424 Staudt

Could innovation in the med dev sector support better care pathways for a burnt-out workforce?

The risk of burnout in the medical space is now at its highest since it was first tracked in 2018. Over 42,400 NHS staff voluntarily quit their jobs in quarter two of last year. Those in the NHS will know that the intensified pressures and responsibiliti

A recent survey by the UK Medical Defence Union has found that 44% regularly feel “exhausted in the morning at the thought of another day at work”. Side effects of sleep deprivation reported by doctors include poor concentration (64%), decision-making difficulties (40%) and mental health problems (30%). Such symptoms are inevitably harmful, as these side effects can cause potentially substandard patient care. Ultimately, navigating burnout’s role in driving compromised patient safety can be difficult to tackle, given the deep-rooted political and resource factors that have exacerbated struggles from the pandemic and before. However, medical device experts Owen Mumford have shared insights on data surrounding burnout-induced substandard care and how medical device innovation can potentially play a role in alleviating pressures on NHS staff. More>>

phone +44 (0) 1993 812021
email Brook Hill Woodstock Oxfordshire OX20 1TU

Veratrak raises £5.3M to accelerate growth

London-based software company Veratrak raises £5.3M to accelerate growth and enhance collaboration, visibility and security across the pharmaceutical industry, and modernise pharmaceutical supply chain operations to get more therapeutics into the hands o

LONDON, 31 JANUARY 2023 00.01: Veratrak, a supply chain SaaS platform purpose built for the life sciences industry, announces £5.3M in Seed funding led by Crane Venture Partners with participation from Seedcamp, Ascension, and Truesight Ventures. The first industry approved commercial blockchain product in the pharmaceutical industry, Veratrak builds and maintains blockchain-based software solutions to better connect pharmaceutical companies with their outsourced partners, from manufacturers to logistics providers and wholesalers. More>>

email Unit 2.05, 12-18 Hoxton St, London N1 6NG
News and Press Releases

BrainEver and 3P Biopharmaceuticals Collaborate on Development of Recombinant Human Homeoprotein Engrailed-1

Noáin, Spain, November 15, 2022: 3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in the process development and cGMP manufacturing of biological products and BrainEver a French biotechnology company focusing on discovering and developing First-in-Class therapies for the treatment of neurodegenerative diseases have entered into a long term collaboration to develop hEng1 a recombinant homeoprotein to treat pathologies such as Amyotrophic Lateral Sclerosis (ALS) or Parkinson's disease.
More info >>

White Papers

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement